3 results
To study the efficacy of the EmBlocker* in heart operations. The EmBlocker* is placed in the thorax cavity and will reroute by the use of ultrasound the emboli in the aorta curve to the aorta descendens, in order to reduce the amount of emboli in…
There will be three formal interim analyses during the study. Interim Analysis 1 will occur at the end of Phase II when approximately 162 PFS events (defined as disease progression or death due to any cause, whichever occurs first) have been…
Primary objective: * To assess the treatment effect on progression-free survival in patients who receive AUY922 on a once-weekly schedule versus patients who receive docetaxel or irinotecanSecondary Objectives* To estimate the overall survival…